The FDA has recently approved these drugs, and some of our customers have added them to their hazardous drug lists. We're sharing this with you so you can add it to your hazardous drug list should you choose.
Check back here often and follow Rpharmy on Twitter for the latest.
- pertuzumab; trastuzumab; hyaluronidase - zzxf (Phesgo®)
- tafasitamab - cxix (Monjuvi®)
- isatuximab - irfc (Sarclisa®)
- trastuzumab; hyaluronidase - oysk (Herceptin Hylecta®)
- calaspargase pegol - mknl (Asparlas®)
- teplizumab (Tzield®)
- mirvetuximab soravtansine (Elahere®)
- mavacamten (Camzyos®)
- oteseconazole (Vivjoa®)
- ganaxolone (Ztalmy®)
- tirzepatide (Mounjaro®)
- tremelimumab (Imjudo®)
- futibatinib (Lytgobi®)
- teclistamab (Tecvayli®)
- pirtobrutinib (JAYPIRCA®)
- elacestrant (Orserdu®)
- mosunetuzumab (Lunsumio®)
- adagrasib (Krazati®)
- olutasidenib (Rezlidhia®)
- anacaulase-bcdb (Nexobrid®)
- elacestrant (Orserdu®)
- retifanlimab (Zynyz®)
- Lurbinectedin (Zepzelca®)
- Epcoritamab-bysp (Epkinly®)
- ritlecitinib (Litfulo®)
- niraparib-abiraterone(Akeega®)
- momelotinib (Ojjaara)
- elranatamab-bcmm (Elrexfio)
- talquetamab-tgvs (Talvey)
- repotrectinib (Augtyro)
- capivasertib (Truqap)
- fruquintinib (Fruzaqla)
- quizartinib (Vanflyta)
- toripalimab-tpzi (Loqtorzi)
- mirikizumab (Omvoh)
- nirogacestat (Ogsiveo)
- eflornithine (Iwilfin™)
